NCIt definition : A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated
antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating
and antineoplastic activities. Upon administration, anti-CD20/anti-CD3 bispecific
antibody MBS303 binds to both T-cells and CD20-expressing B-lineage tumor cells. The
resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response
against the CD20-expressing tumor B-cells. CD20 is exclusively expressed on B-cells
during most stages of B-cell development and is often overexpressed in B-cell malignancies.
MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms
and CD3 molecule with one arm to increase affinity with tumor cells and decrease the
off-target toxicity of T-cells.;
Semantic type(s)